Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus: A Systematic Review

Publikation: Bidrag til tidsskriftLetterpeer review


  1. Clinical use of the co-formulation of insulin degludec and insulin aspart

    Publikation: Bidrag til tidsskriftReviewpeer review

  1. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Drug-drug interaction between warfarin and statins: A Danish cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.

TidsskriftInternational Journal of Clinical Practice
Udgave nummer8
StatusUdgivet - aug. 2020

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 59837607